检测脑膜瘤患者液体活检标本中的诊断和预后基于甲基化的特征。
Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas.
发表日期：2023 Sep 13
作者：
Grayson A Herrgott, James M Snyder, Ruicong She, Tathiane M Malta, Thais S Sabedot, Ian Y Lee, Jacob Pawloski, Guilherme G Podolsky-Gondim, Karam P Asmaro, Jiaqi Zhang, Cara E Cannella, Kevin Nelson, Bartow Thomas, Ana C deCarvalho, Laura A Hasselbach, Kelly M Tundo, Rehnuma Newaz, Andrea Transou, Natalia Morosini, Victor Francisco, Laila M Poisson, Dhananjay Chitale, Abir Mukherjee, Maritza S Mosella, Adam M Robin, Tobias Walbert, Mark Rosenblum, Tom Mikkelsen, Steven Kalkanis, Daniela P C Tirapelli, Daniel J Weisenberger, Carlos G Carlotti, Jack Rock, Ana Valeria Castro, Houtan Noushmehr
来源：
Brain Structure & Function
摘要：
目前，基于手术切除标本的侵入性方法无法准确预测脑膜瘤的复发。通过非侵入性方法识别可能发生复发的患者可以提供治疗策略，无论是干预还是监测。在本研究中，我们分析了来自155例脑膜瘤患者的血液（血清和血浆）和组织样本中的DNA甲基化水平，并与其他中枢神经系统肿瘤和非肿瘤实体进行比较。我们发现了脑膜瘤特异性的DNA甲基化标记物，并使用人工智能创建了准确且通用的模型，用于通过血液或组织样本识别和预测脑膜瘤的复发。本文证明液体活检是诊断和预测脑膜瘤患者预后的潜在非侵入性可靠工具。这种方法可以改进脑膜瘤患者的个体化管理策略。 © 2023. Springer Nature Limited.
Recurrence of meningiomas is unpredictable by current invasive methods based on surgically removed specimens. Identification of patients likely to recur using noninvasive approaches could inform treatment strategy, whether intervention or monitoring. In this study, we analyze the DNA methylation levels in blood (serum and plasma) and tissue samples from 155 meningioma patients, compared to other central nervous system tumor and non-tumor entities. We discover DNA methylation markers unique to meningiomas and use artificial intelligence to create accurate and universal models for identifying and predicting meningioma recurrence, using either blood or tissue samples. Here we show that liquid biopsy is a potential noninvasive and reliable tool for diagnosing and predicting outcomes in meningioma patients. This approach can improve personalized management strategies for these patients.© 2023. Springer Nature Limited.